Wet Age-related Macular Degeneration – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of wet age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the total wet AMD prevalent cases for each country, as well as annualized case counts projected to the national population.

Patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology’s wet AMD forecast answers the following questions:

• How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of wet AMD and the number of new diagnoses of wet AMD?
• Of all people diagnosed with wet AMD, how many in each country in the major mature pharmaceutical markets are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of wet AMD over the forecast period?

In addition to the total wet AMD prevalent cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following wet AMD subpopulations:

• Total mixed prevalent cases of AMD
• Diagnosed and undiagnosed prevalent cases of wet AMD
• Diagnosed drug-treated and non-drug-treated prevalent cases of wet AMD

Note: Coverage may vary by country.